噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征122例  

Tiotropium bromide combined with salmeterol/fluticasone on the treatment of 122 cases with asthma COPD overlap syndrome

作　　者：倪敏讷[1] 童朝晖[2] 

机构地区：[1]清华大学玉泉医院呼吸内科,北京100049 [2]首都医科大学附属北京朝阳医院呼吸内科,北京100020

出　　处：《中国生化药物杂志》2017年第8期206-207,共2页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的 探析噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征的临床疗效。方法 选取122例在本院进行治疗的哮喘-慢阻肺重叠综合征患者,以随机信封法分为2组,试验给予噻托溴铵联合沙美特罗/氟替卡松进行治疗,参照组则给予复方异丙托溴铵联合沙美特罗/氟替卡松进行治疗,观察其临床效果。结果 治疗前,2组患者的肺功能各项指标差异均无统计学意义;治疗后,试验患者的肺功能各项指标的改善程度明显较参照组高（P〈0.05）,急性发作次数与发作时间均优于参照组（P〈0.05）。结论 噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征效果显著,对改善肺功能、降低发作频率等具有一定的临床优势。Objective To evaluate the clinical efficacy of tiotropium combined with salmeterol/fluticasone on the treatment of the patients with asthma COPD overlap syndrome. Methods 122 patients with asthma COPD overlap syndrome were divided into 2 groups by randomized envelope, the experimental group and the control group. The experimental group were given tiotropium bromide combined with salmeterol/fluticasone. The control group were received compound ipratropium bromide combined with salmeterol/fluticasone. The clinical effect was observed. Results Before treatment, there was no significant difference in lung function between the two groups. After treatment, the improvement of pulmonary function indexes in the experimental group was significantly higher than that in the control group （P〈0.05）. And the number of acute attack and attack time in the experimental group were also better than those in the control group （P〈0.05）. Conclusion Tiotropium combined with Shah Mette Lo/fluticasone is effective on the treatment of asthma COPD overlap syndrome, and has some clinical advantages in improving lung function and reducing the frequency of attack.

关 键 词：噻托溴铵 沙美特罗 氟替卡松 哮喘-慢阻肺重叠综合征 

分 类 号：R563[医药卫生—呼吸系统]